Myasthenia gravis activities of daily living profile GI Wolfe, L Herbelin, SP Nations, B Foster, WW Bryan, RJ Barohn Neurology 52 (7), 1487-1487, 1999 | 450 | 1999 |
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (mmt), health … LG Rider, VP Werth, AM Huber, H Alexanderson, AP Rao, N Ruperto, ... Arthritis care & research 63 (S11), S118-S157, 2011 | 392 | 2011 |
Reliability Testing of the Quantitative Myasthenia Gravis Scorea RJ Barohn, D McINTIRE, L Herbelin, GI Wolfe, S Nations, WW Bryan Annals of the New York Academy of Sciences 841 (1), 769-772, 1998 | 392 | 1998 |
The natural history of amyotrophic lateral sclerosis SP Ringel, JR Murphy, MK Alderson, W Bryan, JD England, RG Miller, ... Neurology 43 (7), 1316-1316, 1993 | 288 | 1993 |
Clinical findings in MuSK‐antibody positive myasthenia gravis: a US experience M Pasnoor, GI Wolfe, S Nations, J Trivedi, RJ Barohn, L Herbelin, ... Muscle & Nerve: Official Journal of the American Association of …, 2010 | 208 | 2010 |
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial JM Statland, BN Bundy, Y Wang, DR Rayan, JR Trivedi, VA Sansone, ... Jama 308 (13), 1357-1365, 2012 | 192 | 2012 |
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 186 | 2019 |
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ... The Lancet Neurology 18 (3), 259-268, 2019 | 176 | 2019 |
Challenges in the identification of cobalamin-deficiency polyneuropathy DS Saperstein, GI Wolfe, GS Gronseth, SP Nations, LL Herbelin, ... Archives of neurology 60 (9), 1296-1301, 2003 | 169 | 2003 |
Randomized double‐blind study of botulinum toxin type B for sialorrhea in ALS patients CE Jackson, G Gronseth, J Rosenfeld, RJ Barohn, R Dubinsky, ... Muscle & Nerve: Official Journal of the American Association of …, 2009 | 168 | 2009 |
Pompe disease: literature review and case series M Dasouki, O Jawdat, O Almadhoun, M Pasnoor, AL McVey, ... Neurologic clinics 32 (3), 751-776, 2014 | 159 | 2014 |
Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity CE Jackson, RJ Barohn, G Gronseth, S Pandya, L Herbelin, ... Muscle & nerve 37 (4), 473-476, 2008 | 135 | 2008 |
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis M Pasnoor, J He, L Herbelin, TM Burns, S Nations, V Bril, AK Wang, ... Neurology 87 (1), 57-64, 2016 | 129 | 2016 |
Targeting protein homeostasis in sporadic inclusion body myositis M Ahmed, PM Machado, A Miller, C Spicer, L Herbelin, J He, J Noel, ... Science translational medicine 8 (331), 331ra41-331ra41, 2016 | 126 | 2016 |
Pilot trial of etanercept in the treatment of inclusion-body myositis RJ Barohn, L Herbelin, JT Kissel, W King, AL McVey, DS Saperstein, ... Neurology 66 (1_suppl_1), S123-S124, 2006 | 109 | 2006 |
Non-dystrophic myotonia: prospective study of objective and patient reported outcomes JR Trivedi, B Bundy, J Statland, M Salajegheh, DR Rayan, SL Venance, ... Brain 136 (7), 2189-2200, 2013 | 107 | 2013 |
Randomized phase 2 trial of NP001, a novel immune regulator: Safety and early efficacy in ALS RG Miller, G Block, JS Katz, RJ Barohn, V Gopalakrishnan, M Cudkowicz, ... Neuroimmunology & Neuroinflammation 2 (3), e100, 2015 | 100 | 2015 |
Safety of aerobic exercise in people with diabetic peripheral neuropathy: single-group clinical trial PM Kluding, M Pasnoor, R Singh, LJ D'Silva, M Yoo, SA Billinger, ... Physical therapy 95 (2), 223-234, 2015 | 81 | 2015 |
Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response MK Mittal, RJ Barohn, M Pasnoor, A McVey, L Herbelin, T Whittaker, ... Journal of clinical neuromuscular disease 13 (1), 46-52, 2011 | 69 | 2011 |
Measuring clinical treatment response in myasthenia gravis C Barnett, L Herbelin, MM Dimachkie, RJ Barohn Neurologic clinics 36 (2), 339-353, 2018 | 66 | 2018 |